About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Dr. Reddy's Laboratories Ltd.
Change Company
BSE Code
500124
ISIN Demat
INE089A01031
Book Value
322.47
NSE Code
DRREDDY
Dividend Yield %
0.60
Market Cap
1120172.45
P/E
23.29
EPS
57.64
Face Value
1
1 Week
1 Month
3 Months
6 Months
1 Year
20-Dec-2024
Dr. Reddy’s Laboratories gains despite weakness o...
20-Dec-2024
Dr. Reddy’s Laboratories informs about allotment ...
28-Nov-2024
Dr. Reddy’s Laboratories launches Toripalimab in ...
28-Nov-2024
Dr. Reddy’s Laboratories submits press release
26-Nov-2024
Dr.Reddy's Laboratories informs about analyst meet
26-Nov-2024
Dr.Reddy's Laboratories informs about investor co...
18-Nov-2024
Dr. Reddy's Laboratories’ arm recalling Morphine ...
18-Nov-2024
Clarification sought from Dr Reddys Laboratories...
18-Nov-2024
Dr. Reddy's Laboratories declines on the BSE
14-Nov-2024
Dr. Reddy’s Laboratories informs about disclosure
07-Nov-2024
Dr. Reddy's to invest up to Rs 600 crore in step-...
06-Nov-2024
Dr. Reddy's Laboratories reports 9% fall in Q2 co...
06-Nov-2024
Dr. Reddy's Laboratories jumps despite reporting ...
29-Oct-2024
Dr. Reddy's Laboratories launches drug to treat c...
23-Oct-2024
ISIN Change
Page
1
of
5
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.